Clinical Relevance of NGAL/MMP-9 Pathway in Patients with Endometrial Cancer

Table 2

Comparative analysis of the study groups.

Variable	n	Mean range	Median (95.000%–95.000%)	n	Mean range	Median (95.000%–95.000%)
	Carcinoma endometrium			Normal endometrium
MMP-9; pg/mL	80	8089.6 (6481.1–8891.7)	8234.2 (6341.6–8732.1)	23	5698.2 (3987.1–6341.1)	5712.1 (4251.4–6652.3)	0.001
NGAL; ng/ml	80	180 (120–240)	171 (130–231)	23	110 (90–134)	113 (106–127)	0.002
	Carcinoma endometrium			Polyp endometrium
MMP-9; pg/ml	80	8089.6 (6481.1–8891.7)	8234.2 (6341.6–8732.1)	20	6213.3 (4235.1–7123.8)	6438.1 (4521.2–7234.8)	0.003
NGAL; ng/ml	80	180 (120–240)	171 (130–231)	20	118 (107–150)	110 (99–142)	0.004
	Carcinoma endometrium			Myoma
MMP-9; pg/ml	80	8089.6 (6481.1–8891.7)	8234.2 (6341.6–8732.1)	20	4923.1 (3615.2–6213.4)	5022.1 (3871.4–6431.1)	0.0002
NGAL; ng/ml	80	180 (120–240)	171 (130–231)	20	132 (113–170)	128 (120–161)	0.005